Pre-ECCMID Industry sessions
15:00-16:00
Seegene
Brand new way to check COVID-19 variants
17:00-18:00
Abbott
Combined COVID-19 antigen and antibody rapid testing in SARS-CoV-2 suspected patients: impact on infection confirmation rates and cost-effectiveness
12:30-13:30
bioMérieux
New fully automated TB-IGRA solution for Tuberculosis infection detection
17:00-18:00
Qiagen
End TB: increasing access to TB testing with effective IGRA solutions
10:30-11:30
GSK
Monoclonal antibodies for the treatment of COVID-19: Current evidence and future landscape
13:00-14:00
Qiagen
Unlocking the research potential of QuantiFERON Monitor for COVID-19
15:00-16:00
Bruker Daltonics GmbH & Co. KG
17:00-18:00
Seegene
The new era of COVID-19
18:30-19:00
Gilead
Expert opinions on the role of antiviral therapy in the management of hospitalised patients with COVID-19: Translating data into practice
11:00-11:30
Bruker Daltonics GmbH & Co. KG
Fighting Sepsis with innovative ID/AST Solutions - Today and Tomorrow
12:30-14:00
MSD
Gram-negative Resistance: Positive Updates in a Gram-negative World
15:00-16:00
Abbott
The value of CRP Point-of-Care testing in the fight against antimicrobial resistance
17:00-18:00
bioMérieux
The double-edged sword of COVID-19 on the use of antibiotics
18:30-19:00
GSK
The Troubles with UTIs: Surveillance, Sequelae and a Landscape changed by COVID
